Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 323.06% from the company’s current […]
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 323.06% from the company’s current […]
